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Abstract: In this study we investigated the relationship between the calcium channel blockers (CCBs), amlodipine, felodip-
ine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, verapamil and diltiazem, and their calculated molecular 
descriptors: polar surface area (PSA), molecular weight (Mw), volume value (Vol), aqueous solubility data (logS), lipophilic-
ity (logP), acidity (pKa values) and plasma protein binding (PPB) data, obtained from relevant literature. The relationships 
between the computed molecular properties of selected CCBs and their PPB data were investigated by simple linear regres-
sion analysis that revealed very low correlations (R2<0.35). When multiple linear regression (MLR) analysis was applied to 
investigate reliable correlations between the CCBs’ calculated molecular descriptors and PPB data, the best correlations were 
found for the relationships between CCBs, and PPB data and lipophilicity, and with application of the molecular descriptor 
(Mw, Vol, or pKa) data as additional independent variables (R2=0.623; R2=0.741; R2=0.657, respectively), with an accept-
able probability value (P<0.05), confirming that lipophilicity, together with other molecular properties, are essential for the 
drugs’ PPB. We conclude that this could be considered as an additional in vitro approach for modeling CCBs.
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INTRODUCTION
High blood pressure or hypertension is a global health 
problem. Calcium channel blockers (CCBs) are widely 
used drugs in cardiovascular medicine for the treat-
ment of hypertension, angina pectoris, supraventricu-
lar dysrhythmias, hypertrophic cardiomyopathy or 
after myocardial infarction [1-5]. According to avail-
able literature data, CCBs have variable oral bioavail-
ability (from 5% for nisoldipine, through 58% for 
nifedipine, to about 80% for amlodipine) due to an 
extensive first-pass metabolism of most of these drugs. 
Their half-life is relatively short, mostly less than 12 h, 
with the exception of amlodipine. The plasma protein 
binding values (PPB) of CCBs are relatively similar 
and they are ranged from 75% for diltiazem to 99% 
for felodipine and nisoldipine. They have dual routes 
of elimination, renal and fecal [1-5]. 
CCBs can be combined with other antihyperten-
sive drugs, such as angiotensin receptor blockers or 
drugs which block the rennin-angiotensin system [1-
5]. The drugs’ properties such as absorption, distribu-
tion, plasma protein binding, metabolism and routes 
of elimination noticeably influence their clinical suc-
cess [6]. On the other hand, the number of the drugs’ 
physical and chemical properties significantly influ-
ence these properties and consequently the clinical 
success of drugs. 
Lipophilicity, molecular weight, molecular vol-
ume, polar surface area, acidity and solubility play 
important roles in drugs absorption, penetration into 
tissues, distribution, plasma protein binding and the 
route of elimination [7-10]. The molecules with high 
lipophilicity show a higher degree of absorption, high-
er plasma protein binding, better penetration into tis-
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sues and distribution compared to the less lipophilic 
ones. Also, weakly lipophilic drugs are mostly elimi-
nated in the urine, while highly lipophilic drugs usual-
ly exhibit a high degree of fecal elimination, according 
to the well-known Lipinski “rule of 5”. However, this 
rule also predicts that low absorption or permeation 
of drugs is more likely when there are more than 5 
hydrogen-bond donors, 10 hydrogen-bond acceptors, 
if the molecular weight is greater than 500 and the 
calculated logP is greater than 5 [11].
A number authors have studied various antihyper-
tensive drugs, including CCBs, their design and syn-
thesis [12,13], pharmacokinetics, pharmacodynamics 
and efficacy [14-17]. We have examined the correla-
tions between the calculated molecular descriptors, 
mainly the lipophilicity of selected antihypertensive 
drugs, their PPB data, absorption and elimination in 
established and appropriate models [18-22]. The aim 
of the present study was to estimate the relationship 
between plasma protein binding data of nine CCBs 
(amlodipine, felodipine, isradipine, nicardipine, nife-
dipine, nimodipine, nisoldipine, verapamil and diltia-
zem) and their in silico molecular properties.
MATERIALS AND METHODS
Nine frequently used CCBs, amlodipine, felodipine, 
isradipine, nicardipine, nifedipine, nimodipine, nisol-
dipine, verapamil, diltiazem, were investigated (Table 
1). The software package Molinspiration Depiction 
Software (www.molinspiration.com) was used for the 
calculation of electronic descriptors, polar surface 
area (PSA), the constitutional parameter, molecular 
weight (Mw) and the geometric descriptor, volume 
value (Vol). The CCBs aqueous solubility data (logS) 
as well as the CCBs lipophilicity descriptors, nine dif-
ferent logP values (AlogPs, AClogP, AB/logP, milogP, 
AlogP, MlogP, KOWWINlogP, XLOGP2, XLOGP3) 
were calculated using the software package Virtual 
Computational Chemistry Laboratory (www.vcclab.
org) Chemdraw ultra 12.0 was used for calculating 
another lipophilicity parameter – ClogP values. The 
software package DrugBank (www.drugbank.ca) was 
used for the calculation the acidity descriptor, pKa. 
The relationships between CCB PPB data and dif-
ferent molecular descriptors were investigated using 
multiple linear regression analysis (MLR). The calcu-
lated molecular descriptors are presented in Table 2. 
Microsoft Excel 2003 and Origin 7.0 PRO (Origin Lab 
Corporation, USA) were used for statistical analysis. 
The data for the PPB were obtained from the relevant 
literature [2] and are presented in Table 2.
RESULTS AND DISCUSSION
According to literature data, CCBs have relatively 
similar and high values of PPB that range from 75% 
for diltiazem, to 99% for felodipine and nisoldipine 
(Table 2) [2]. The molecular descriptors were calculat-
ed using four different software packages (Table 2). To 
assess PPB of CCBs using in silico molecular descrip-
tors, correlations between CCBs plasma and PPB data 
obtained from relevant literature and all six calculat-
ed molecular descriptors (PSA, Mw, Vol, logP, pKa, 
logS) were initially investigated using simple linear 
Table 1. The investigated CCBs.
1. Amlodipine
3-ethyl-5-methyl2-[(2-aminoethoxy)
methyl]-4-(2-chlorophenyl)-6-methyl-1,4-
dihydropyridine-3,5-dicarboxylate;
2. Felodipine
3-ethyl-5-methyl4-(2,3-dichlorophenyl)-
2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate;
3. Isradipine
3-methyl-5-propan-2-yl-4-(2,1,3-benzoxa-
diazol-4-yl)-2,6-dimethyl-1,4-dihydropyri-
dine-3,5-dicarboxylate;
4. Nicardipine
3-{2-[benzyl(methyl)amino]ethyl} 5-methyl 
2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-
pyridine-3,5-dicarboxylate;
5. Nifedipine
3,5-dimethyl-2,6-dimethyl-4-(2-
nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate;
6. Nimodipine
3-(2-methoxyethyl)-5-propan-2-yl-2,6-
dimethyl-4-(3-nitrophenyl)-1,4-dihydropyr-
idine-3,5-dicarboxylate;
7. Nisoldipine
3-methyl 5-(2-methylpropyl) 2,6-dimethyl-
4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate;
8. Verapamil
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-
dimethoxyphenyl)ethyl](methyl)amino}-2-
(propan-2-yl)pentanenitrile;
9. diltiazem
(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-
methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-
1,5-benzothiazepin-3-yl acetate.
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regression, which in most cases provided very poor 
correlations, with coefficients R2<0.10. The only cor-
relation between CCB data regarding PPB and their 
calculated values of PSA, pKa and ClogP provided 
slightly higher correlations, with R2~0.35. Examina-
tion of the relationships between CCB PPB data and 
different molecular descriptors Mw, Vol and pKa data 
as additional independent variables by MLR provided 
significantly higher correlations (R2=0.623; R2=0.741; 
R2=0.657 respectively) with acceptable probability val-
ues (P<0.05). The obtained correlations are presented 
by the following equations as follows:
Eq.1:
PPB.pred (%) = 4.945(±1.632)ClogP–0.103(±0.049)
Mw+117.607(±18.612),
with n=9; R2=0.623; S.D.=5.229; F=4.962;
Eq.2:
PPBpred (%)=5.420(±1.383)ClogP–0.103(±0.034)
Vol+111.770(±11.342),
with n=9; R2=0.741; S.D.=4.339; F=8.569;
Eq.3:
PPBpred (%)=3.692(±1.411)ClogP–2.129(±0.92)
pKa+94.745(±8.063),
with n=9; R2=0.657; S.D.=4.987; F=5.756.
The established correlations can be considered 
as good [23]. All values of CCBs’ PPB data predicted 
using the above equations are presented in Table 2 
and Fig. 1.
All calculated descriptors play important roles 
in the drugs’ absorption, distribution, metabolism, 
elimination as well as plasma protein binding [24,25]. 
In the first step of the investigation, the correlations 
between CCBs and PPB data obtained from relevant 
literature and all calculated descriptors were investi-
gated using simple linear regression. The PPB data 
and their calculated molecular descriptors showed 
very low correlations, with R2 lower than 0.10. Only 
for correlations between PPB data and the molecular 
descriptors PSA, pKa, and ClogP were better. Follow-
ing this preliminary investigation, in the next stage 
of the study, the relationships between PPB and two 
different CCB molecular descriptors were investigated 
using MLR. ClogP as a lipophilicity descriptor was 
initially chosen as the first independent variable, since 
from all lipophilicity descriptors it showed the best 
Table 2. The CCBs calculated molecular descriptors as well as plasma protein binding degree data collected from relevant literature (1) 
and predicted using ClogP and Mw (2); ClogP and Vol values (3); ClogP and pKa values (4).
1. Amlodipine 2. Felodipine 3. Isradipine 4. Nicardipine 5. Nifedipine 6. Nimodipine 7. Nisoldipine 8. Verapamil 9. Diltiazem
ClogP 3.43 2.24 3.92 5.23 3.13 4.00 4.58 4.47 1.19
pKa 9.46 5.39 5.33 8.18 5.33 5.41 5.32 9.68 8.18
logS -4.02 -4.64 -3.15 -4.63 -3.76 -4.19 -4.40 -4.79 -3.90
Mw 408.9 384.3 371.4 479.5 346.3 418.4 388.4 454.6 414.5
Vol 363.9 323.3 330.1 437.4 302.8 378.8 353.0 454.3 377.7
PSA 100 65 104 114 110 120 110 64 59
PPB (1) 93 99 95 96 96 96 99 90 75
PPB (2) 92 89 99 94 97 94 100 93 81
PPB (3) 93 91 99 95 98 95 100 89 79
PPB (4) 87 92 98 97 95 98 100 91 82
Fig. 1. Relationships between the PPB data of the investigated 
CCBs. The data were obtained from [2] (S1) and predicted using 
ClogP and Mw (S2), ClogP and Vol (S3), and ClogP and pKa val-
ues (S4). The numbers refer to the CCBs as presented in Table 1.
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correlations with the CCB PPB data, the values of Mw, 
Vol, pKa and logS were chosen as possible, second 
independent variables; the values of the electronic de-
scriptor PSA could not be used since the correlation 
of R2 with ClogP values was 0.39.
Lipophilicity is one of the most important physi-
cochemical properties of a drug. Lipophilic molecules 
have higher absorption, penetration into tissues and a 
wider distribution. Molecules with higher lipophilicity 
[26,27] show higher values of PPB in comparison to 
the less lipophilic compounds with similar proper-
ties. Lipophilicity can be characterized by the par-
tition coefficient (logPO/W) in n-octanol/water. The 
so-called shake flask method is a traditional technique 
for experimental determination of a molecule’s logP 
values, as a measure of its lipophilicity. Thin-layer 
chromatography as well as high-performance liquid 
chromatography are established methods for evaluat-
ing a molecule’s lipophilicity. For structurally differ-
ent compounds, these methods can yield a significant 
amount of retention data, which can be well correlated 
with their lipophilicity [26,27]. The calculated logP 
values and in silico-obtained hydrophobicity param-
eters, are generally accepted measures of a drug’s li-
pophilicity [26,27].
The numbers of lipophilicity descriptors (ClogP, 
AlogP, MlogP, KOWWINlogP, AlogPs, AClogP, AB/
logP, milogP, XLOGP2, XLOGP3) were calculated for 
the investigated group of CCBs using several different 
software packages. Different logP can be calculated 
by substructure-based and property-based methods 
[26,27], with two groups of substructure-based meth-
ods: fragmental and atom-based. The fragmental-
based methods cut molecules into different fragments, 
and after application of correction factors and sum-
ming all fragment contributions, logP (ClogP, KOW-
WINlogP, MilogP) is obtained. The atom-based meth-
ods (AlogP, XlogP2, XlogP3) cut molecules to single 
atoms and usually do not apply corrections [26,27]. 
The property-based methods use the description of 
the entire molecules, including methods based on to-
pological descriptors, methods based on molecules’ 
3D-structure or empirical methods (AlogPs) [26,27]; 
the distinctions between absolute logP values of se-
lected CCBs are caused by the differences between the 
calculation methods [26,27].
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